RecruitingPhase 3ACTRN12605000581662

PRACTICAL TRIAL

Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increase after Coronary intervention in Acute coronary Lesions

Sponsor

Cardiology Dept, Royal Perth Hospital

Enrollment

370 participants

Start Date

Jan 1, 2004

Study Type

Interventional

Conditions

Acute Coronary Syndromes

Summary

A multi-centre, randomised, double-blind, clinical trial comparing a 600mg versus 300mg loading dose of Clopidogrel on the Incidence of Myonecrosis and Laboratory Measures of Platelet Inhibition following early Percutaneous Coronary Intervention in Acute Coronary Syndrome patients.

Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

This study (called the PRACTICAL Trial) is comparing two different loading doses of a blood-thinning medication called clopidogrel in patients undergoing emergency heart procedures (percutaneous coronary intervention, or PCI) for acute coronary syndrome (ACS). ACS includes heart attacks and unstable angina. Clopidogrel helps prevent blood clots in the arteries after a stent is placed. Researchers are comparing a standard 300mg dose to a higher 600mg dose to see which one better protects the heart muscle. You may be eligible if: - You have abnormal ECG (heart tracing) results - Your blood tests show evidence of heart muscle damage (elevated troponin I or T) - You have known coronary artery disease (previous heart attack, stenting, bypass surgery, or a positive stress test) You may NOT be eligible if: - There are no specific exclusion criteria listed for this study Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.